AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$ADRX

SR ONE CAPITAL MANAGEMENT, LLC purchased $27.2M of ADRX (indirect holdings)

SR ONE CAPITAL MANAGEMENT, LLC purchased 1,600,000 indirectly-held shares of ADARx Pharmaceuticals, Inc. (ADRX) at $17.00 ($27.20M total) across 3 trades on 2026-09-28.

Original reporting
SEC EDGAR · SR ONE CAPITAL MANAGEMENT, LLC
Published Sep 30, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ADRX
Bullish
medium confidence
Mentioned
$ADRX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADRXBullishMed
01

Why it matters

The purchase adds credibility to the company's pipeline and may attract other investors.

02

Market read

Insider buying of $27M in ADRX is a material event that could influence short‑term price action.

03

What to watch

Potential dilution from future financing rounds could offset buying pressure.

Relevance 8/10Novelty 7/10Timing: post‑market filing on 2026‑09‑29

Background

Form 4 filing reveals a new insider stake increase for ADRX.

Company-level read

Ticker impact

$ADRXBullishMedium confidence
Context

SR ONE CAPITAL MANAGEMENT purchased 1,600,000 shares of ADRX at $17 each, a $27.2M buy that raised its stake to 10% ownership.

Expected impact

likely upward pressure as the market prices in the insider buying

Evidence & confidence

A $27M buy by a 10% owner is material for a micro‑cap biotech and often precedes short‑term price appreciation.

Market effects

Sector

May boost sentiment toward small‑cap biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider buying could be a defensive move ahead of upcoming clinical data risk.

Key entities

  • Investor
    SR ONE CAPITAL MANAGEMENT, LLC

    10% owner of ADRX after the purchase.

  • Company
    ADRX

    ADARx Pharmaceuticals, Inc., a biotech listed on Nasdaq.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ADRX insider trading history →

Related articles

SEP 29
$ADRXHighAI 9/10

ADARx’s $446m IPO signals investor appetite for RNA therapeutics

ADARx Pharmaceuticals raised $446.3 million in its upsized IPO, pricing 26.25 million shares at $17.00 each. The company, focused on RNA therapeutics, began trading on Nasdaq under 'ADRX'. It plans to use the proceeds to advance its pipeline, including treatments for genetic disorders and obesity. AbbVie will own 4.9% post-IPO.

bioxconomy.com2 min
SEP 28
$ADRXHighAI 8/10

Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?

ADARx Pharmaceuticals aims to raise up to $371.9 million in a U.S. IPO, targeting a $1.74 billion valuation. The company plans to offer 21.9 million shares at $15-$17 each, listing on Nasdaq as ADRX. AbbVie Inc. (ABBV) will invest up to $100 million, gaining a 4.9% stake. ADARx has multiple drugs in development, with onvuzosiran in late-stage testing for hereditary angioedema. The IPO market remains selective, favoring companies with later-stage assets.

insidermonkey.com2 min